Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Diet in women with breast cancer compared to healthy controls - What is the difference?

Hagen KB, Aas T, Kvaløy JT, Søiland H, Lind R.

Eur J Oncol Nurs. 2018 Feb;32:20-24. doi: 10.1016/j.ejon.2017.11.003. Epub 2017 Nov 24.

PMID:
29353628
2.

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H.

Breast Cancer Res. 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.

3.

Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.

Klebaner D, Hamilton-Dutoit S, Ahern T, Crawford A, Jakobsen T, Cronin-Fenton DP, Damkier P, Janssen E, Kjaersgaard A, Ording AG, Søiland H, Sørensen HT, Lash TL, Hellberg Y.

PLoS One. 2017 Mar 16;12(3):e0171453. doi: 10.1371/journal.pone.0171453. eCollection 2017.

4.

Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

Solbrække KN, Søiland H, Lode K, Gripsrud BH.

Med Health Care Philos. 2017 Mar;20(1):89-103. doi: 10.1007/s11019-016-9737-y.

PMID:
27709396
5.

Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls.

Hagen KB, Aas T, Kvaløy JT, Eriksen HR, Søiland H, Lind R.

Breast. 2016 Aug;28:100-6. doi: 10.1016/j.breast.2016.05.005. Epub 2016 Jun 2.

PMID:
27262826
6.

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients.

Egeland NG, Lunde S, Jonsdottir K, Lende TH, Cronin-Fenton D, Gilje B, Janssen EA, Søiland H.

Int J Mol Sci. 2015 Oct 14;16(10):24243-75. doi: 10.3390/ijms161024243. Review.

7.

Capturing the Experience: Reflections of Women With Breast Cancer Engaged in an Expressive Writing Intervention.

Gripsrud BH, Brassil KJ, Summers B, Søiland H, Kronowitz S, Lode K.

Cancer Nurs. 2016 Jul-Aug;39(4):E51-60. doi: 10.1097/NCC.0000000000000300.

8.

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells.

Helland T, Gjerde J, Dankel S, Fenne IS, Skartveit L, Drangevåg A, Bozickovic O, Flågeng MH, Søiland H, Mellgren G, Lien EA.

PLoS One. 2015 Apr 13;10(4):e0122339. doi: 10.1371/journal.pone.0122339. eCollection 2015.

9.

Illness uncertainty in breast cancer patients: validation of the 5-item short form of the Mishel Uncertainty in Illness Scale.

Hagen KB, Aas T, Lode K, Gjerde J, Lien E, Kvaløy JT, Lash TL, Søiland H, Lind R.

Eur J Oncol Nurs. 2015 Apr;19(2):113-9. doi: 10.1016/j.ejon.2014.10.009. Epub 2014 Dec 20.

PMID:
25538036
10.

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.

Lien EA, Søiland H, Lundgren S, Aas T, Steen VM, Mellgren G, Gjerde J.

Breast Cancer Res Treat. 2013 Sep;141(2):243-8. doi: 10.1007/s10549-013-2677-9. Epub 2013 Sep 1.

11.

Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.

Søiland H, Hagen KB, Gjerde J, Lende TH, Lien EA.

Acta Oncol. 2013 May;52(4):861-2. doi: 10.3109/0284186X.2012.742963. Epub 2012 Nov 29. No abstract available.

PMID:
23193962
12.

Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1937-43. doi: 10.1158/1055-9965.EPI-11-0419. Epub 2011 Jul 12.

13.

[Hypotension and oxygen saturation fall in a woman during sentinel lymph node biopsy].

Johnsen L, Ilsaas C, Salthe J, Lende TH, Bjerkeset O, Søiland H.

Tidsskr Nor Laegeforen. 2011 May 6;131(8):840-1. doi: 10.4045/tidsskr.10.0108. Norwegian. No abstract available.

14.

Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.

Gilje B, Nordgård O, Tjensvoll K, Janssen EA, Søiland H, Smaaland R, Baak JP.

Breast Cancer Res Treat. 2011 Jul;128(1):137-46. doi: 10.1007/s10549-011-1487-1. Epub 2011 Apr 8.

PMID:
21476002
15.

The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer.

Zhang H, Slewa A, Janssen E, Skaland I, Yu Y, Gudlaugsson E, Feng W, Kjellevold K, Søiland H, Baak JP.

Anticancer Res. 2011 Feb;31(2):443-9.

PMID:
21378322
16.

D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.

Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP.

Mod Pathol. 2011 Apr;24(4):502-11. doi: 10.1038/modpathol.2010.199. Epub 2011 Feb 11.

17.

In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!

Lende TH, Janssen EA, Gudlaugsson E, Voorhorst F, Smaaland R, van Diest P, Søiland H, Baak JP.

J Clin Oncol. 2011 Mar 1;29(7):852-8. doi: 10.1200/JCO.2009.25.0407. Epub 2010 Dec 28.

PMID:
21189388
18.

Biologic profiling of lymph node negative breast cancers by means of microRNA expression.

Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Søiland H, Baak JP.

Mod Pathol. 2010 Dec;23(12):1567-76. doi: 10.1038/modpathol.2010.177. Epub 2010 Sep 3.

19.

Patients with clinical/radiological hyperplasia of mammary glands show pathological persistence of temperature of skin points.

Li H, Shen X, Ying J, Zhao L, Jin M, Thu S, Sun C, Voorhorst F, Soiland H, Lende T, Baak JP.

Anticancer Res. 2009 Nov;29(11):4697-702.

20.

LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.

Janssen EA, Øvestad IT, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP.

Cell Oncol. 2009;31(5):335-43. doi: 10.3233/CLO-2009-0479.

21.

Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.

Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.

Acta Oncol. 2009;48(4):514-21. doi: 10.1080/02841860802620613.

PMID:
19107621
22.

Prognostic relevance of androgen receptor detection in operable breast cancer.

Søiland H, Kørner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, Baak JP, Søreide JA.

J Surg Oncol. 2008 Dec 1;98(7):551-8. doi: 10.1002/jso.21156.

PMID:
18937259
23.

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.

Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Søiland H, Janssen EA, Zur Hausen A.

Breast Cancer Res Treat. 2009 May;115(2):241-54. doi: 10.1007/s10549-008-0126-y. Epub 2008 Jul 30. Review.

PMID:
18665447
24.

Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis.

Søiland H, Skaland I, van Diermen B, Janssen EA, Körner H, Varhaug JE, Søreide JA, Baak JP.

Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):362-70. doi: 10.1097/PAI.0b013e31815b9c92.

PMID:
18528280
25.

Comparison of apolipoprotein D determination methods in breast cancer.

Søiland H, Skaland I, Janssen EA, Gudlaugsson E, Körner H, Varhaug JE, Søreide JA, Baak JP.

Anticancer Res. 2008 Mar-Apr;28(2B):1151-60.

26.

Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.

Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak JP.

Breast Cancer Res Treat. 2009 Mar;114(1):39-45. doi: 10.1007/s10549-008-9980-x. Epub 2008 Mar 29.

PMID:
18373192
27.

Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.

Søiland H, Janssen EA, Kørner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA.

Breast Cancer Res Treat. 2009 Feb;113(3):519-28. doi: 10.1007/s10549-008-9955-y. Epub 2008 Mar 11.

PMID:
18330697
28.

Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.

Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak JP.

Mod Pathol. 2007 Dec;20(12):1307-15. Epub 2007 Oct 5.

29.

Emerging concepts of apolipoprotein D with possible implications for breast cancer.

Søiland H, Søreide K, Janssen EA, Körner H, Baak JP, Søreide JA.

Cell Oncol. 2007;29(3):195-209. Review.

30.

Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years.

Janssen EA, Søiland H, Skaland I, Gudlaugson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP.

Cell Oncol. 2007;29(1):25-35.

31.

Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years.

Janssen EA, van Diest PJ, Søiland H, Gudlaugson E, Nysted A, Voorhorst FJ, Vermorken JB, Søreide JA, Baak JP.

Cell Oncol. 2006;28(5-6):295-303.

32.

Resuscitative emergency thoracotomy in a Scandinavian trauma hospital--is it justified?

Søreide K, Søiland H, Lossius HM, Vetrhus M, Søreide JA, Søreide E.

Injury. 2007 Jan;38(1):34-42. Epub 2006 Nov 2.

PMID:
17083941
33.

Microsatellite instability in colorectal cancer.

Söreide K, Janssen EA, Söiland H, Körner H, Baak JP.

Br J Surg. 2006 Apr;93(4):395-406. Review.

PMID:
16555243
34.

Benign peritoneal cystic mesothelioma.

Søreide JA, Søreide K, Körner H, Søiland H, Greve OJ, Gudlaugsson E.

World J Surg. 2006 Apr;30(4):560-6.

PMID:
16547615
35.

Acute pancreatitis in a young girl with the Netherton syndrome.

Söreide K, Söiland H, Körner H, Haga H, Söreide JA.

J Pediatr Surg. 2005 Nov;40(11):e69-72.

PMID:
16291148
36.

[Treatment of varicose leg ulcer].

Soiland H, Eskeland G.

Tidsskr Nor Laegeforen. 1975 Aug 20;95(23):1305-9. Norwegian. No abstract available.

PMID:
1101435
37.

Lengthening a finger with the "on the top" method.

SOILAND H.

Acta Chir Scand. 1961 Sep;122:184-6. No abstract available.

PMID:
13914818
38.

[Surgery of the hand; plastic reconstruction of the injured hand].

SOILAND H.

Tidsskr Nor Laegeforen. 1958 Feb 15;78(4):128-30. Norwegian. No abstract available.

PMID:
13543815
39.

Tilfelle til diagnose.

SØILAND H.

Nord Med. 1948 Sep 10;39(37):1655. Undetermined Language. No abstract available.

PMID:
18213785
40.

A new plate for osteosynthesis.

SOILAND H.

Acta Chir Scand. 1947 Oct 20;96(2):178-84. No abstract available.

PMID:
20271714

Supplemental Content

Loading ...
Support Center